Jiménez-Ríos G, Balderas-Delgado C, Vargas-Bravo CA, Díaz-Hernández PI, Velasco-Vargas CA, Velázquez-Guerrero D, Casillas-Franco X, Sánchez-Báez J, Ramírez-López T, Medina-Baltazar D, Trejo-Fuentes B

Language: Spanish
References: 4
Page: 45-49
PDF size: 225.36 Kb.

ABSTRACT

Hodgkin lymphoma (HL) is a monoclonal B-cell neoplasm, which mainly affects the lymph nodes and is usually characterized by the presence of abnormal cells called Reed-Sternberg (RS) cells. The therapeutic approach has changed over time with the introduction and modification of new chemotherapy regimens and hematopoietic stem cell transplantation (HSCT) which is the infusion of "progenitor cells" (SC) in order to restore marrow function and immune, as well as support for patients who have received high doses of chemotherapy and whose hematological toxicity would limit its administration. The Hematopoietic Transplant Unit of the Ixtapaluca Regional Hospital of High Specialty began its work in December 2021 and so far 4 transplants have been carried out on patients with Hodgkin's lymphoma. Among the results, it was shown that more than 60 days after the HSCT, the patients were asymptomatic and with a complete response at the end of this period, all reaching normal levels of neutrophils, leukocytes, and platelets, without the presence of B symptoms and without new palpable lymph node growths.

REFERENCES

1. Oliveros AJW, Sandoval CC, Cires DRS, Blum MMA, Tafur CAJ. Trasplante de células hematopoyéticas. Medicina. 2003; 9: 174-185.

2. Languasco A, Larotonda R, Makiya M. Trasplante de células progenitoras hematopoyéticas. Argentina: Sociedad Argentina de Hematología. An Sist Sanit Navar. 2017; 2006; 29 (Supl. 2): 137-152.

3. Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL et al. Linfoma de Hodgkin. Rev Hematol Mex. 2019; 20 (2): 124-130.

4. Labardini J, Cervera E, Corrales C et al. Oncoguía: linfoma de Hodgkin. Cancerología. 2011; 6: 133-138.